- FDA approves Takeda's Brintellix for depression
- Kaiser Family Foundation releases animated video explaining how ACA will impact Americans
- Major trend for 2014: Personalization
- Award-winning McKesson Patient Relationship Solutions on display at McKesson ideaShare 2013
- Walgreens ups Sona Chawla to role of president of digital and chief marketing officer
NEW YORK — Patients taking an investigative antidepressant undergoing late-stage clinical development showed “significant” improvement, according to study results released Monday.
Forest Labs and Pierre Fabre Medicament announced results of a phase-3 trial of levomilnacipran in adults with major depressive disorder. Results showed a statistically significant improvement in patients treated with the drug, compared with those taking placebo.
“Depressed patients often struggle to find the right antidepressant, and the need for new medications is high,” Forest Research Institute SVP research and development Marco Taglietti said. “These positive phase-3 results are very encouraging and support the continued research of levomilnacipran in adult patients with major depressive disorder.”